• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Study shows blood pressure reduction with Medtronic renal denervation procedure

Study shows blood pressure reduction with Medtronic renal denervation procedure

September 19, 2022 By Sean Whooley

Symplicity Spyral renal denervation system Medtronic
The Symplicity Spyral renal denervation system delivers energy to the nerves leading to the kidneys, which help regulate blood pressure. [Image courtesy of Medtronic]
Medtronic (NYSE:MDT) announced study data that it says demonstrates significant blood pressure reduction with the Symplicity renal denervation system.

The SYMPLICITY HTN-3 clinical trial observed subjects who underwent radiofrequency renal denervation (RF RDN) with first-generation Symplicity. Results demonstrated a statistically significant reduction in office and ambulatory blood pressure compared to a sham control group.

Medtronic’s RDN minimally invasive procedure delivers radiofrequency energy to specific nerves near the kidneys that can become overactive and cause high blood pressure.

Data, presented at the 34th Transcatheter Cardiovascular Therapeutics (TCT) conference in Boston, was also published in The Lancet.

Analysts have remained bullish on Medtronic’s RDN treatment, despite last year’s news that it had to continue its pivotal Spyral HTN-ON MED trial into this year after failing to obtain the positive results needed to end enrollment early for the potential hypertension treatment. The present plan is for Medtronic to present Spyral HTN-ON MED results at the American Heart Association Scientific Sessions this November. Spyral HTN-ON MED is the final piece of Medtronic’s FDA submission for Symplicity Spyral.

Also, at TCT 2022, ReCor Medical announced that a trial for its Paradise ultrasound renal denervation (uRDN) treatment met its primary efficacy endpoint.

SYMPLICITY HTN-3 trial details

SYMPLICITY HTN-3 evaluated 535 patients with treatment-resistant hypertension, randomized 2:1. After six months, 101 patients in the sham arm underwent RDN treatment. At three years, the RDN group presented a 26.4 mm Hg reduction in office systolic blood pressure. That compared to a 5.7 mm Hg reduction in the sham group.

Patients experienced a 15.6 mm Hg reduction in 24-hour ambulatory systolic blood pressure in the RDN group. The sham group produced a 0.3 mm Hg reduction.

A total of 535 patients with treatment resistant hypertension were randomized 2:1 to RDN (n=364) vs. sham control (n=171). After six months, 101 patients in the sham control arm underwent treatment with RDN (crossover group). When conducting a longer-term analysis with all available data, and accounting for control crossover patients by using their last observation carried forward (imputation), the results through three years are as follows:

On average, 17.5% of RDN patients spent time in target range, compared to 8.2% in the sham group. Medtronic said Symplicity demonstrated long-term safety in line with expected outcomes for the patient population.

“These findings provide important insights into the evolution of patients’ blood pressure control, with and without renal denervation, in a scenario more akin to the real-world setting— under everyday physician management without the frequent follow up visits and monitoring that occur in research settings,” said Dr. Deepak L. Bhatt, executive director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School and co-principal investigator for the trial.

Bhatt said the results illustrate that, for certain patients with high blood pressure, it remains poorly controlled. This puts them at risk for cardiovascular complications such as stroke, he added.

Medtronic found “much to learn” in trial data

“While we did not find a significant six-month blood pressure reduction difference in RDN versus sham in HTN-3, we felt that there was much to learn by following HTN-3 patients for a longer time period, particularly in those sham patients with sustained blood pressure elevations who ‘crossed over’ to RDN,” said Dr. Jeffrey Popma CMO for the Coronary & Renal Denervation business and the Structural Heart & Aortic business at Medtronic. “Using standard imputation methods for BP comparison in cross-over patients, we were pleased to see a sustained benefit in three-year blood pressure reduction in HTN-3 patients treated with RDN.

“This study adds important, incremental information to the totality of evidence now supporting the long-term effect of RDN in patients with hypertension. Documentation of medication compliance and improvements made to the new Spyral catheter may have the potential to further influence clinical outcomes in patients enrolled in the SPYRAL portfolio of studies.”

Medtronic is committed to pushing treatment forward

Jason Weidman, Medtronic SVP and president of the Coronary & Renal Denervation business, added that the data provides “a greater understanding” of long-term patient behavior and RDN impacts.

“We remain deeply committed to this adjunctive hypertension treatment option and look forward to data from additional studies, including the Spyral HTN-ON MED extension trial, which we plan to have at the American Heart Association Scientific Sessions, subject to acceptance,” Weidman said.

Medtronic’s Symplicity Spyral renal denervation is available in more than 60 countries. However, it remains investigational in the U.S., as well as in Japan and Canada.

In May, the company presented data demonstrating the benefit of the Symplicity blood pressure procedure with Simplicity Spyral.

Filed Under: Blood Management, Cardiovascular, Clinical Trials, Featured, News Well Tagged With: Medtronic, renal denervation, Transcatheter Cardiovascular Therapeutics symposium (TCT)

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy